Incyte secured European Commission approval for its once-daily oral therapy Povofortay to treat adults with moderate-to-severe hidradenitis suppurativa. The endorsement expands the drugmaker's immunology portfolio beyond its flagship blood cancer treatment Jakafi. The approval provides a new revenue driver as competition intensifies against established therapies.
Incyte Wins EU Approval for Skin Drug
The European Commission approved Incyts oral therapy Povofortay for adults with severe hidradenitis suppurativa. The drug expands Incyts immunology portfolio as it awaits a US regulatory decision expected early next year.
Xurve View
Insights:
Xurve View










